Companies in #Chronic Hepatitis B (HBV)
Found 2 companies operating in this sector.
Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for liver and viral diseases, with a lead focus on chronic hepatitis B. Its pipeline includes pevifoscorvir sodium, a capsid assembly modulator in Phase 2b for chronic HBV; ALG-055009, a THR-beta agonist in Phase 2a for metabolic dysfunction-associated steatohepatitis (MASH) and obesity; and ALG-097558, a ritonavir-free pan-coronavirus protease inhibitor that has completed Phase 1. In Q2 2026 the company reported $27.8 million in revenue, driven by a $25 million China licensing deal, and narrowed its net loss to $1.5 million.
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company headquartered in Warminster, Pennsylvania developing a curative regimen for chronic hepatitis B virus (HBV) infection. The company employs a three-pronged strategy — suppress viral antigens, reduce HBV DNA, and boost the host immune system — using a combination of its lead RNAi therapeutic imdusiran (AB-729) with immunomodulators including AB-101, an oral PD-L1 inhibitor. As of July 2026 the company's lead program (IM-PROVE I and IM-PROVE II combination trials) is in Phase 2a and the company's mRNA delivery technology is also the subject of active patent litigation against Moderna and Pfizer/BioNTech over COVID-19 vaccine IP. Arbutus was originally incorporated in 2005 as OnCore BioPharma before merging with Tekmira Pharmaceuticals in 2015 and adopting the Arbutus name.